GlucoTrack, Inc. (GCTK) Income Statement
GCTK 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGCTK revenue and net income
GCTK profit margins
GCTK growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GCTK quarterly EPS vs estimates
GlucoTrack beat the analyst EPS estimate in 0 of the last 1 quarters. Next report: November 12, 2026.
GCTK income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $70,778 | $208,000 | $43,488 | $589,462 | $611,689 |
| Cost of revenue | — | $36,000 | $13,000 | $23,000 | $42,000 | $47,000 | $51,000 | $95,563 | $140,209 | $59,584 |
| Gross profit | — | −$36,000 | −$13,000 | −$23,000 | −$42,000 | −$47,000 | $208,000 | −$52,075 | $449,253 | $552,105 |
| Research & development | $9.8M | $9.5M | $4.7M | $2.0M | $1.8M | $1.5M | $1.6M | $3.0M | $3.2M | $2.9M |
| Sales, general & admin | $6.3M | $5.0M | $2.4M | $2.5M | $2.1M | $1.6M | $1.5M | $3.5M | $7.8M | $3.2M |
| Total operating expenses | $16.1M | $14.5M | $7.1M | $4.4M | $4.0M | $3.1M | −$3.3M | −$6.5M | −$10.0M | −$5.0M |
| Operating income | −$16.1M | −$14.5M | −$7.1M | −$4.4M | −$4.0M | −$3.1M | $3.5M | $6.5M | $10.6M | $5.7M |
| Interest income | — | $62,000 | $7,000 | $11,000 | $26,000 | $98,000 | — | — | — | — |
| Interest expense | — | $628,000 | $0 | $3,000 | $4.2M | $98,000 | $10,000 | $18,290 | $24,396 | $16,216 |
| Income before taxes | −$19.4M | −$22.6M | −$7.1M | −$4.4M | −$4.1M | −$2.7M | −$3.5M | −$6.7M | −$10.3M | −$5.4M |
| Income taxes | — | $22.6M | $855,000 | $3,000 | $33,000 | −$98,000 | $43 | −$13.2M | $24,396 | $16,216 |
| Net income | −$19.4M | −$22.6M | −$7.1M | −$4.4M | −$4.1M | −$2.7M | −$3.5M | −$6.7M | −$10.3M | −$5.4M |
| EBITDA | −$19.3M | −$21.9M | −$7.1M | −$4.4M | −$3.9M | −$3.1M | −$3.5M | −$6.6M | −$10.2M | −$5.3M |
| EPS (diluted) | −$323.13 | −$2797.95 | −$2098.34 | −$0.28 | −$0.88 | −$341.62 | −$290.01 | −$17849.60 | −$1.87 | −$83596.54 |
| Gross margin | — | — | — | — | — | −66.4% | 100.0% | −119.7% | 76.2% | 90.3% |
| Operating margin | — | — | — | — | — | −4,425.1% | 1,685.6% | 15,035.4% | 1,794.2% | 924.6% |
| Net margin | — | — | — | — | — | −3,809.1% | −1,690.4% | −15,442.0% | −1,752.2% | −884.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $24,000 | $0 | $0 | $0 | $42,000 | $0 |
| Cost of revenue | $21,000 | $22,000 | $14,000 | $9,000 | $11,000 | $8,000 | $14,000 | $10,000 | $8,000 | $4,000 | $21,000 | $14,000 |
| Gross profit | −$21,000 | −$22,000 | −$14,000 | −$9,000 | −$11,000 | −$8,000 | −$14,000 | −$10,000 | −$8,000 | −$4,000 | $21,000 | −$14,000 |
| Research & development | $2.0M | $2.1M | $1.6M | $3.2M | $3.1M | $1.9M | $1.7M | $2.1M | $3.6M | $2.1M | $1.7M | $1.7M |
| Sales, general & admin | $1.4M | $2.1M | $2.3M | $1.0M | $1.6M | $1.6M | $2.1M | $1.1M | $902,000 | $803,000 | $672,000 | $531,000 |
| Total operating expenses | $3.4M | $4.2M | $3.5M | −$4.3M | $4.8M | $3.5M | $25.2M | −$3.3M | $4.5M | $3.0M | $11.8M | −$2.2M |
| Operating income | −$3.4M | −$4.2M | −$3.5M | $4.3M | −$4.8M | −$3.5M | −$25.2M | $3.3M | −$4.5M | −$3.0M | −$11.8M | $2.2M |
| Interest income | $0 | — | — | — | $29,000 | — | — | — | $2,000 | — | — | — |
| Interest expense | — | — | $125,000 | — | — | — | — | $1.8M | — | $24,000 | $1,000 | $1,000 |
| Income before taxes | −$3.8M | −$4.3M | −$3.6M | −$4.2M | −$4.8M | −$6.8M | −$10.1M | −$5.1M | −$4.5M | −$2.9M | −$2.4M | −$2.2M |
| Income taxes | — | — | — | — | — | — | $39,276 | — | — | −$39,276 | $12,000 | −$14,000 |
| Net income | −$3.8M | −$4.3M | −$3.6M | −$4.2M | −$4.8M | −$6.8M | −$10.1M | −$5.1M | −$4.5M | −$2.9M | −$2.4M | −$2.2M |
| EBITDA | −$3.8M | −$4.3M | −$3.6M | −$4.3M | −$4.7M | −$6.8M | −$11.3M | −$3.2M | −$4.5M | −$2.9M | −$2.4M | −$2.2M |
| EPS (diluted) | −$0.76 | — | — | −$4.64 | −$9.62 | −$40.35 | −$19.51 | −$1091.07 | −$983.76 | −$703.61 | −$692.70 | −$580.70 |
| Gross margin | — | — | — | — | — | — | −58.3% | — | — | — | 50.0% | — |
| Operating margin | — | — | — | — | — | — | −105,166.7% | — | — | — | −28,073.8% | — |
| Net margin | — | — | — | — | — | — | −42,058.3% | — | — | — | −5,742.9% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GCTK's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GCTK financial results
GlucoTrack reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $19.4 million. Diluted earnings per share came to −$323.13.
See the GCTK stock overview for the latest quote and news, or the GCTK chart for price history and technical indicators.
GCTK income statement FAQ
Does GlucoTrack have revenue?
GlucoTrack reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is GlucoTrack profitable?
No. GlucoTrack reported a net loss of $19.4 million in fiscal 2025.
How much does GlucoTrack spend on research and development?
GlucoTrack spent $9.8 million on research and development in fiscal 2025.
What are GlucoTrack's earnings per share?
GlucoTrack earned $-323.13 per diluted share in fiscal 2025, compared with $-2797.95 a year earlier.
When will GlucoTrack report its next earnings?
GlucoTrack is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does GlucoTrack's fiscal year end?
GlucoTrack's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.